Nasopharyngeal carcinoma · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Gemcitabine (GC) Variant #34 | — | R 15 338 | 56d | 7.4 mo | 27.9 mo | 5 | R 76 690 PFS proxy | 8 |
Cisplatin and Epirubicin Variant #01 | — | R 2 458 | 21d | — | — | — | — | 1 |
TPC Variant #01 | — | R 2 327 | 21d | — | — | — | — | — |
Cisplatin and Fluorouracil (CF) Variant #29 | — | R 1 900 | 21d | 20.1 mo | 18.6 mo | 30 | R 57 002 PFS proxy | 3 |
Lobaplatin and Fluorouracil Variant #01 Partial | — | R 550 | 21d | — | — | — | — | 1 |
DCF N/A - secondary systemic drug | — | R 228 | 21d | — | — | — | — | 1 |
No induction Partial | — | — | — | — | — | — | — | 3 |
7 of 7 regimens shown